Drug intelligence / Profile preview

SLC022

Development stage: Discontinued
Lead developer: Solace Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

SLC022 is an orally administered small molecule drug developed as a glial cell modulator for the treatment of pain, specifically post-herpetic neuralgia. It was initially developed by Solace Pharmaceuticals. The drug acts by modulating glial cells, which play an active role in neuronal pain signaling and are considered a novel target for chronic pain management. SLC022 demonstrated efficacy in preclinical pain models and advanced to Phase 2 clinical trials for post-herpetic neuralgia but its development has since been discontinued.

Other names: SLC-022SLC022SLC 022

Beyond the preview

Go deeper on SLC022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLC022.

Explore the full profile